174 related articles for article (PubMed ID: 22605570)
1. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.
Curiel-Lewandrowski C; Swetter SM; Einspahr JG; Hsu CH; Nagle R; Sagerman P; Tangrea J; Parnes H; Alberts DS; Chow HH
Cancer; 2012 Dec; 118(23):5848-56. PubMed ID: 22605570
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells.
Fogli S; Banti I; Stefanelli F; Picchianti L; Digiacomo M; Macchia M; Breschi MC; Lapucci A
Eur J Med Chem; 2010 Nov; 45(11):5100-7. PubMed ID: 20801552
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
[TBL] [Abstract][Full Text] [Related]
4. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines.
Han EK; Arber N; Yamamoto H; Lim JT; Delohery T; Pamukcu R; Piazza GA; Xing WQ; Weinstein IB
Breast Cancer Res Treat; 1998 Apr; 48(3):195-203. PubMed ID: 9598866
[TBL] [Abstract][Full Text] [Related]
5. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
[TBL] [Abstract][Full Text] [Related]
6. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
[TBL] [Abstract][Full Text] [Related]
7. Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
Rice PL; Goldberg RJ; Ray EC; Driggers LJ; Ahnen DJ
Cancer Res; 2001 Feb; 61(4):1541-7. PubMed ID: 11245463
[TBL] [Abstract][Full Text] [Related]
9. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
10. The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon.
Mladenova D; Daniel JJ; Dahlstrom JE; Bean E; Gupta R; Pickford R; Currey N; Musgrove EA; Kohonen-Corish MR
Gut; 2011 Mar; 60(3):350-60. PubMed ID: 20980345
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
12. The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway.
Singh R; Cadeddu RP; Fröbel J; Wilk CM; Bruns I; Zerbini LF; Prenzel T; Hartwig S; Brünnert D; Schroeder T; Lehr S; Haas R; Czibere A
Apoptosis; 2011 Sep; 16(9):889-901. PubMed ID: 21739277
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis.
Chaudhary SC; Singh T; Kapur P; Weng Z; Arumugam A; Elmets CA; Kopelovich L; Athar M
Toxicol Appl Pharmacol; 2013 May; 268(3):249-55. PubMed ID: 23274568
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.
Segawa E; Hashitani S; Toyohara Y; Kishimoto H; Noguchi K; Takaoka K; Urade M
Oncol Rep; 2009 Apr; 21(4):869-74. PubMed ID: 19287981
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in mouse lung explants.
Bouchard L; Castonguay A
Drug Metab Dispos; 1993; 21(2):293-8. PubMed ID: 8097699
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.
Linden KG; Leachman SA; Zager JS; Jakowatz JG; Viner JL; McLaren CE; Barr RJ; Carpenter PM; Chen WP; Elmets CA; Tangrea JA; Lim SJ; Cochran AJ; Meyskens FL
Cancer Prev Res (Phila); 2014 May; 7(5):496-504. PubMed ID: 24614012
[TBL] [Abstract][Full Text] [Related]
17. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence.
Asgari MM; Maruti SS; White E
J Natl Cancer Inst; 2008 Jul; 100(13):967-71. PubMed ID: 18577752
[TBL] [Abstract][Full Text] [Related]
18. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
[TBL] [Abstract][Full Text] [Related]
19. Multicentre double-blind study of the efficacy, safety and tolerance of pirazolac compared with sulindac in patients with rheumatoid arthritis.
Numo R
Drugs Exp Clin Res; 1990; 16(1):17-27. PubMed ID: 2198156
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo.
Cassidy PB; Liu T; Florell SR; Honeggar M; Leachman SA; Boucher KM; Grossman D
Cancer Prev Res (Phila); 2017 Jan; 10(1):36-44. PubMed ID: 27920018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
